Skip To Main Content
Patient and Caregiver Site

Preparation & Administration

Quick Links
Preparation Into an Intravenous Bag
Preparation for Intravenous Syringe
COLUMVI® Administration
Recommended Premedications

Administer COLUMVI diluted solution via intravenous bag infusion. The 2.5 mg dose may also be administered via intravenous syringe infusion.

Inspection before preparation

1. Inspect

Prior to administration, visually inspect the solution for particulate matter and discoloration. Discard the vial if the solution:

  • Appears cloudy or discolored
  • Contains visible particles
Dosing instructions

2. Prepare

Prepare COLUMVI for intravenous infusion using the aseptic technique.

Step-up dosing vial

3. Calculate

Use the chart below to determine the dose, total volume of COLUMVI solution, and the number of COLUMVI vials needed.

Preparation into an intravenous bag1

  1. Withdraw and discard the appropriate volume of Sodium Chloride
    According to the chart below, withdraw the volume of 0.9% Sodium Chloride Injection or 0.45% Sodium Chloride Injection from the infusion bag and discard.
  2. Withdraw and dilute COLUMVI
    Use a sterile needle and syringe to withdraw the required volume of COLUMVI from the vial(s) and dilute into the infusion bag to a final concentration of 0.1 mg/mL to 0.6 mg/mL according to the chart below. Discard any unused portion left in the vial(s).
  3. Mix
    Gently invert the infusion bag to mix the solution to avoid excessive foaming. Do not shake.
Dilution of COLUMVI into an intravenous infusion bag
Dose of COLUMVI Size of 0.9% Sodium Chloride Injection or 0.45% Sodium Chloride Injection infusion bag Volume to be withdrawn and discarded from the infusion bag Volume of COLUMVI to be added to the infusion bag Total volume to be infused
2.5 mg 50 mL 27.5 mL 2.5 mL 25 mL
10 mg 50 mL 10 mL 10 mL 50 mL
100 mL 10 mL 10 mL 100 mL
30 mg 50 mL 30 mL 30 mL 50 mL
100 mL 30 mL 30 mL 100 mL

Preparation of 2.5 mg dose into an intravenous syringe1

Only the 2.5 mg dose may be administered via the alternative method of preparation into an intravenous syringe, as outlined below.

  1. Draw Sodium Chloride into syringe
    Draw 22.5 mL of 0.9% Sodium Chloride Injection or 0.45% Sodium Chloride Injection into a 30 mL syringe composed of polypropylene (PP) (see chart below).
  2. Withdraw 2.5 mL of COLUMVI from vial
    Withdraw 2.5 mL of COLUMVI from the vial using a sterile needle into a second syringe (see chart below). Discard any unused COLUMVI left in the vial.
  3. Dilute COLUMVI
    Attach a connector to the two syringes and transfer COLUMVI into the 30 mL syringe. The final concentration of COLUMVI should be 0.1 mg/mL.
  4. Prep and invert syringe
    • Disconnect the syringes. Draw air into the syringe containing the COLUMVI diluted solution and close
    • Gently invert the syringe to mix the solution, in order to avoid excessive foaming. Do not shake
    • Remove air bubbles from the syringe before administration
Dilution of COLUMVI into an intravenous syringe
Dose of COLUMVI Volume of 0.9% Sodium Chloride Injection or 0.45% Sodium Chloride Injection to be added to the syringe Volume of COLUMVI to be added to the syringe Total volume to be infused
2.5 mL 22.5 mL 2.5 mL 25 mL

COLUMVI administration1

  • COLUMVI should only be administered:
    • By a healthcare professional with immediate access to appropriate medical support, including supportive medications to manage severe CRS
    • As an intravenous infusion only through a dedicated infusion line that includes a sterile 0.2-micron in-line filter using an intravenous infusion pump or syringe pump. Prime the infusion line with the diluted infusion solution
  • To ensure the entire dose of COLUMVI is administered, replace the empty infusion bag or syringe with an infusion bag or syringe containing 0.9% Sodium Chloride Injection or 0.45% Sodium Chloride Injection connected to the same infusion line. Continue the infusion at the same rate until the recommended infusion duration is reached

Do not mix COLUMVI with other drugs.

Resource material

Please see Section 2.5, 2.6, and 2.7 of the COLUMVI Prescribing Information to learn more about preparing and administering COLUMVI and for a list of compatible IV infusion bags, syringes, and infusion sets

Recommended premedications to reduce the risk of CRS and infusion-related reactions1

Premedications to be administered for COLUMVI infusion

Patients requiring premedication

All patients

Premedication

Administration

Dexamethasone 20 mg intravenously*

Completed at least 1 hour prior to COLUMVI infusion

Acetaminophen 500 to 1000 mg orally

At least 30 minutes before COLUMVI infusion

Antihistamine (diphenhydramine 50 mg orally or intravenously or equivalent)

Completed at least 30 minutes before COLUMVI infusion

Patients requiring premedication

All patients

Premedication

Administration

Acetaminophen 500 to 1000 mg orally

At least 30 minutes before COLUMVI infusion

Antihistamine (diphenhydramine 50 mg orally or intravenously or equivalent)

Completed at least 30 minutes before COLUMVI infusion

Patients requiring premedication

Patients who experienced any grade CRS with the previous dose

Premedication

Administration

Dexamethasone 20 mg intravenously*

Completed at least 1 hour prior to COLUMVI infusion

*If dexamethasone is not available, administer prednisone 100 mg, prednisolone 100 mg, or methylprednisolone 80 mg intravenously.

Tumor Lysis Syndrome Prophylaxis

Before starting COLUMVI, administer anti-hyperuricemics to patients at risk of tumor lysis syndrome, ensure adequate hydration status, and monitor as appropriate.

Infection Prophylaxis

Before starting COLUMVI, consider initiation of antiviral prophylaxis to prevent herpes virus reactivation. Consider prophylaxis for cytomegalovirus infection, pneumocystis jirovecii pneumonia (PJP), and other opportunistic infections in patients at increased risk.

Medication vial

Dosing, Administration, and Pharmacy Guide

A guide to dosing and administration for 3L+ DLBCL treatment.

Download

CRS=cytokine release syndrome.

Contact a representative

Interested in more information about COLUMVI?

Contact Us
Dose modifications

See administration details following dose delays or adverse reactions

Learn More
NEXT: CRS Risk Mitigation Strategies

Important Safety Information & Indication

Indication

COLUMVI (glofitamab-gxbm) is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL), or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy.

This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Important Safety Information

BOXED WARNING: Cytokine Release Syndrome (CRS), including serious or fatal reactions, can occur in patients receiving COLUMVI. Premedicate before each dose, and initiate treatment with the COLUMVI step-up dosing schedule to reduce the risk of CRS. Withhold COLUMVI until CRS resolves or permanently discontinue based on severity.

Warnings and Precautions

Cytokine Release Syndrome (CRS)

COLUMVI can cause serious and fatal CRS.

Among the 145 patients who received COLUMVI, CRS occurred in 70%, with Grade 1 CRS developing in 52% of patients, Grade 2 in 14%, Grade 3 in 2.8% of patients, and Grade 4 in 1.4%. The most common manifestations of CRS included fever, tachycardia, hypotension, chills, and hypoxia.

CRS occurred in 56% of patients after the 2.5 mg dose of COLUMVI, 35% after the 10 mg dose, 29% after the initial 30 mg target dose, and 2.8% after subsequent doses. With the first step-up dose of COLUMVI, the median time to onset of CRS (from the start of infusion) was 14 hours (range: 5 to 74 hours). CRS after any dose resolved in 98% of cases, with a median duration of CRS of 2 days (range: 1 to 14 days). Recurrent CRS occurred in 34% of all patients. CRS can first occur with the 10 mg dose; of 135 patients treated with the 10 mg dose of COLUMVI, 15 patients (11%) experienced their first CRS event with the 10 mg dose, of which 13 events were Grade 1, 1 event was Grade 2, and 1 event was Grade 3.

Administer COLUMVI in a facility equipped to monitor and manage CRS. Initiate therapy according to the COLUMVI step-up dosing schedule to reduce the risk of CRS, administer pretreatment medications, and ensure adequate hydration. Patients should be hospitalized during and for 24 hours after completing infusion of the 2.5 mg step-up dose. Patients who experienced any grade CRS during the 2.5 mg step-up dose should be hospitalized during and for 24 hours after completion of the 10 mg step-up dose. For subsequent doses, patients who experienced Grade ≥2 CRS with their previous infusion should be hospitalized during and for 24 hours after the next COLUMVI infusion.

At the first sign of CRS, immediately evaluate patients for hospitalization, manage per current practice guidelines, and administer supportive care; withhold or permanently discontinue COLUMVI based on severity.

Neurologic Toxicity

COLUMVI can cause serious neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity (ICANS).

Among 145 patients who received COLUMVI, the most frequent neurologic toxicities of any grade were headache (10%), peripheral neuropathy (8%), dizziness or vertigo (7%), and mental status changes (4.8%, including confusional state, cognitive disorder, disorientation, somnolence, and delirium). Grade 3 or higher neurologic adverse reactions occurred in 2.1% of patients and included somnolence, delirium, and myelitis. Cases of ICANS of any grade occurred in 4.8% of patients.

Coadministration of COLUMVI with other products that cause dizziness or mental status changes may increase the risk of neurologic toxicity. Optimize concomitant medications and hydration to avoid dizziness or mental status changes. Institute fall precautions as appropriate.

Monitor patients for signs and symptoms of neurologic toxicity, evaluate, and provide supportive therapy; withhold or permanently discontinue COLUMVI based on severity.

Evaluate patients who experience neurologic toxicity such as tremors, dizziness, or adverse reactions that may impair cognition or consciousness promptly, including potential neurology evaluation. Advise affected patients to refrain from driving and/or engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery, until the neurologic toxicity fully resolves.

Serious Infections

COLUMVI can cause serious or fatal infections.

Serious infections were reported in 16% of patients, including Grade 3 or 4 infections in 10%, and fatal infections in 4.8% of patients. Grade 3 or higher infections reported in ≥ 2% patients were COVID-19 infection (6%), including COVID-19 pneumonia, and sepsis (4.1%). Febrile neutropenia occurred in 3.4% of patients.

COLUMVI should not be administered to patients with an active infection. Administer antimicrobial prophylaxis according to guidelines. Monitor patients before and during COLUMVI treatment for infection and treat appropriately. Withhold or consider permanent discontinuation of COLUMVI based on severity.

Tumor Flare

COLUMVI can cause serious tumor flare. Manifestations included localized pain and swelling at the sites of the lymphoma lesions and/or dyspnea from new pleural effusions.

Tumor flare was reported in 12% of patients who received COLUMVI, including Grade 2 tumor flare in 4.8% of patients and Grade 3 tumor flare in 2.8%. Recurrent tumor flare occurred in two (12%) of the affected patients. Most tumor flare events occurred during Cycle 1, with a median time to first onset of 2 days (range: 1 to 16 days) after the first dose of COLUMVI. The median duration was 3.5 days (range: 1 to 35 days).

Patients with bulky tumors or disease located in close proximity to airways or a vital organ should be monitored closely during initial therapy. Monitor for signs and symptoms of compression or obstruction due to mass effect secondary to tumor flare, and institute appropriate treatment. Withhold COLUMVI until tumor flare resolves.

Embryo-Fetal Toxicity

Based on its mechanism of action, COLUMVI may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with COLUMVI and for 1 month after the last dose.

Most Common Adverse Reactions

The most common (≥ 20%) adverse reactions, excluding laboratory abnormalities, are CRS (70%), musculoskeletal pain (21%), rash (20%), and fatigue (20%). The most common Grade 3 to 4 laboratory abnormalities (≥ 20%) are lymphocyte count decreased (83%), phosphate decreased (28%), neutrophil count decreased (26%), uric acid increased (23%), and fibrinogen decreased (21%).

Drug Interactions

For certain CYP substrates where minimal concentration changes may lead to serious adverse reactions, monitor for toxicities or drug concentrations of such CYP substrates when coadministered with COLUMVI.

Glofitamab-gxbm causes the release of cytokines that may suppress the activity of CYP enzymes, resulting in increased exposure of CYP substrates. Increased exposure of CYP substrates is more likely to occur after the first dose of COLUMVI on Cycle 1 Day 8 and up to 14 days after the first 30 mg dose on Cycle 2 Day 1 and during and after CRS.

Use in Specific Populations

Lactation
There are no data on the presence of glofitamab-gxbm in human milk or the effects on the breastfed child or milk production. Because human IgG is present in human milk, and there is potential for glofitamab-gxbm absorption leading to B-cell depletion, advise women not to breastfeed during treatment with COLUMVI and for 1 month after the last dose of COLUMVI.

Geriatric Use
Of the 145 patients with relapsed or refractory LBCL who received COLUMVI in study NP30179, 55% were 65 years of age or older, and 23% were 75 years of age or older. There was a higher rate of fatal adverse reactions, primarily from COVID-19, in patients 65 years of age or older compared to younger patients. No overall differences in efficacy were observed between patients 65 years of age or older and younger patients.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see the COLUMVI full Prescribing Information for additional Important Safety Information, including BOXED WARNING.

    • COLUMVI. Prescribing Information. Genentech, Inc.

      COLUMVI. Prescribing Information. Genentech, Inc.

    • Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-cell Lymphomas V.1.2026. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed December 22, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org

      Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-cell Lymphomas V.1.2026. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed December 22, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org

    • Ip A, Mutebi A, Wang T, et al. Treatment outcomes with standard of care in relapsed/refractory diffuse large B-cell lymphoma: real-world data analysis. Adv Ther. 2024;41(3):1226-1244. doi:10.1007/​s12325-023-02775-9

      Ip A, Mutebi A, Wang T, et al. Treatment outcomes with standard of care in relapsed/refractory diffuse large B-cell lymphoma: real-world data analysis. Adv Ther. 2024;41(3):1226-1244. doi:10.1007/​s12325-023-02775-9

    • Bacac M, Colombetti S, Herter S, et al. CD20-TCB with obinutuzumab pretreatment as next generation treatment of hematologic malignancies. Clin Cancer Res. 2018;24(19):4785-4797. doi:10.1158/​1078-0432. CCR-18-0455

      Bacac M, Colombetti S, Herter S, et al. CD20-TCB with obinutuzumab pretreatment as next generation treatment of hematologic malignancies. Clin Cancer Res. 2018;24(19):4785-4797. doi:10.1158/​1078-0432. CCR-18-0455

    • Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387(24):2220-2231. doi:10.1056/​NEJMoa2206913

      Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387(24):2220-2231. doi:10.1056/​NEJMoa2206913

    • Data on file. Genentech, Inc.

      Data on file. Genentech, Inc.

    • Food and Drug Administration. Center for Drug Evaluation and Research. Multi-Discipline Review. Accessed March 1, 2025. https://www.accessdata.fda.gov/​​drugsatfda_docs/​​nda/​​2023/​​761309Orig1s000MultidisciplineR.pdf

      Food and Drug Administration. Center for Drug Evaluation and Research. Multi-Discipline Review. Accessed March 1, 2025. https://www.accessdata.fda.gov/​​drugsatfda_docs/​​nda/​​2023/​​761309Orig1s000MultidisciplineR.pdf

    +